100% Tariff on Imported Drugs Reshapes Pharma Supply Chains
The U.S. pharmaceutical industry experienced a significant change when President Trump signed a proclamation imposing a 100% tariff on imported drugs and their active pharmaceutical ingredients (APIs). Citing national security concerns, the administration invoked Section 232 of the Trade Expansion Act of 1962, pointing to the fact that more than half of the U.S. drug supply is produced overseas.
The policy will take effect on July 31, 2026, for major manufacturers, with a later deadline of September 29 for smaller companies. The move represents a major shift in U.S. trade policy, using tariffs to encourage domestic production and reduce the nation’s reliance on foreign-made drugs and APIs.
Tariff Structure and Relief Programs: A Strategic Shift for Big Pharma
The new tariff system introduces a tiered structure that imposes a 100% tariff on imported patented drugs and APIs as the base rate. However, companies can reduce their tariffs by committing to onshoring production within the U.S. The policy lays out several conditions for tariff relief:
- 100% tariff: The standard rate for imported drugs and APIs with no special agreements.
- 20% tariff: For companies that submit and gain approval for onshoring plans, which require moving manufacturing to the U.S.
- 0% tariff: For companies that enter into Most Favored Nation (MFN) pricing agreements and fully commit to U.S.-based production.
The goal of this policy is not only to raise costs for foreign-sourced drugs but also to incentivize pharmaceutical companies to bring more production to the U.S., ensuring a more regionally focused supply chain.
Impact on Pharma Companies: Onshoring and Domestic Manufacturing Plans
In response to the tariff threat, several major pharmaceutical companies have pledged billions of dollars to build domestic manufacturing facilities. These commitments are part of a broader strategy to meet U.S. policy requirements and reduce the financial burden of the new tariffs. The following companies have announced significant plans:
- Eli Lilly is set to invest $27 billion in the construction of four new U.S. sites, including three for API production.
- Merck has committed $70 billion, which includes a new $1 billion biologics facility in Delaware.
- Johnson & Johnson revealed a $55 billion plan to expand its U.S. manufacturing capacity for critical therapeutics.
These efforts signal a shift in pharmaceutical manufacturing that will reduce reliance on overseas production. However, the process of building new plants and scaling up production is expected to take years, which could lead to temporary price volatility during the transition period.
Exemptions and Strategic Focus: Generics and Specialty Drugs Remain Protected
While the 100% tariff primarily targets branded drugs and patented APIs, certain exemptions are included to avoid disrupting critical healthcare sectors. Generic drugs and biosimilars are exempt from the tariff for at least one year, allowing companies to continue importing these products without the added tax. This gives manufacturers time to adjust to the new tariff policy on branded products.
In addition to generics, several specialty drugs are also protected under the new policy. These include:
- Orphan drugs: Used for rare diseases affecting small patient populations.
- Nuclear medicines: Vital for cancer treatments and other serious conditions.
- Fertility treatments and cell/gene therapies: Essential for advanced patient care.
The protection of these specialty categories ensures that vulnerable patients maintain access to essential therapies, at least temporarily. However, these exemptions are likely to be reassessed in the coming years as the industry adapts to the new tariff system.
Challenges Ahead: Price Volatility and Long-Term Supply Chain Shifts
Although certain categories of drugs are exempt, the transition to domestic manufacturing will not be without its challenges. Economists warn that the shift toward onshoring will likely lead to price volatility as pharmaceutical companies adjust to new regulatory requirements and logistical complexities.
The OECD has estimated that it may take eight to ten years for the U.S. pharmaceutical industry to fully recover the costs of transitioning to domestic production. In the interim, U.S. consumers may face higher drug prices as manufacturers absorb the costs of building new facilities, obtaining regulatory approvals, and shifting supply chains.
The adjustment period will also require upgrading and expanding U.S. manufacturing capabilities, which may struggle to meet the demand for certain drugs in the short term. These delays could contribute to supply chain disruptions, further affecting pricing and availability.
Geopolitical Repercussions and Global Trade Tensions
The imposition of 100% tariffs has raised concerns from global pharmaceutical leaders, particularly in the European Union. EU drug exports to the U.S. amounted to over $127 billion in 2024, and the new tariffs threaten to disrupt these vital trade relationships. Some European governments are worried that the tariffs will disrupt global supply chains and affect the flow of medicines to the U.S.
The policy also leaves China largely unaffected, as many of the APIs currently imported from China are not subject to the tariffs. The continued dependence on Chinese APIs creates challenges for U.S. companies seeking to reduce foreign dependency. These issues underscore the complex geopolitical landscape surrounding U.S. pharmaceutical production and trade policy.













